Want to see IL:AMDA full AI Analyst Report?
Top Page
Almeda Pu
(TASE:AMDA)
Select Model
Select Model
Rating:63Neutral
Price Target:
270.00
▲(10.11% Upside)
Action:Reiterated
Date:08/25/26
The score is driven primarily by financial quality concerns—persistent negative operating/free cash flow and volatile results—despite a conservatively financed balance sheet. Valuation is a meaningful offset (low P/E and very high dividend yield). Technicals are supportive on trend (price above key moving averages) but mixed on momentum, limiting the overall upside in the score.
Positive Factors
Conservative balance sheet
Minimal leverage and a substantial equity base provide financial resilience and reduce solvency risk. This buffer gives the company flexibility to absorb operating volatility and sustain activity without heavy dependence on creditors.
Negative Factors
Persistent negative cash generation
Recurring operating and free cash outflows indicate that reported earnings are not converting into cash. This weakens self-funding capacity and may require external financing or use of balance-sheet resources to maintain operations.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Minimal leverage and a substantial equity base provide financial resilience and reduce solvency risk. This buffer gives the company flexibility to absorb operating volatility and sustain activity without heavy dependence on creditors.
Read all positive factors
Almeda Pu (AMDA) vs. iShares MSCI Israel ETF (EIS)
Market Cap
₪52.70M
Dividend Yield22.84%
Average Volume (3M)9.94K
Price to Earnings (P/E)1.7
Beta (1Y)-0.11
Revenue Growth-52.44%
EPS GrowthN/A
CountryIL
Employees2
SectorGeneral
Sector StrengthN/A
IndustryAsset Management
Share Statistics
EPS (TTM)N/A
Shares Outstanding19,395,714
10 Day Avg. Volume8,094
30 Day Avg. Volume9,940
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)0.38
Price to Sales (P/S)112.85
P/FCF Ratio-9.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Almeda Pu Business Overview & Revenue Model
Company Description
Almeda Ventures Limited Partnership, established in Tel Aviv, Israel, in 2020, functions as a venture capital firm. The partnership strategically deploys capital across various development stages, including seed, startup, early-stage, and establis...
Almeda Pu Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
78
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 10.74M | 87.68K | -3.02M | -292.00K | 907.00K | 1.60M |
| Gross Profit | 10.73M | -57.37K | -3.04M | -328.00K | 852.00K | 1.56M |
| EBITDA | 9.94M | 1.91M | -4.28M | -1.55M | -562.00K | 98.00K |
| Net Income | 9.97M | 1.89M | -4.20M | -1.58M | -641.00K | 52.00K |
Balance Sheet | ||||||
| Total Assets | 30.87M | 25.96M | 23.08M | 25.71M | 27.28M | 27.91M |
| Cash, Cash Equivalents and Short-Term Investments | 13.33M | 4.40M | 2.35M | 2.91M | 5.93M | 9.54M |
| Total Debt | 0.00 | 0.00 | 15.00K | 73.00K | 147.00K | 243.00K |
| Total Liabilities | 93.00K | 125.03K | 442.00K | 405.00K | 393.00K | 545.00K |
| Stockholders Equity | 30.78M | 25.84M | 22.64M | 25.31M | 26.88M | 27.37M |
Cash Flow | ||||||
| Free Cash Flow | -982.00K | -1.07M | -1.09M | -1.13M | -1.46M | -1.29M |
| Operating Cash Flow | -982.00K | -1.07M | -1.09M | -1.13M | -1.46M | -1.28M |
| Investing Cash Flow | 13.23M | -476.29K | -1.41M | -3.57M | -2.15M | -9.93M |
| Financing Cash Flow | -947.00K | 1.54M | 1.48M | -73.00K | 59.00K | 8.24M |
Almeda Pu Peers Comparison
UnderperformOutperform
Sector (55)
IL:AMDA
Almeda Pu
264.10
128.26
94.42%
IL:CBI
Clal Biotech
24.10
-11.70
-32.68%
IL:BLRX
Bioline Rx
1.40
-0.70
-33.33%
IL:CANF
Can Fite Bio
376.40
375.40
37540.00%
IL:ALMD
Allmed Solution
30.40
-3.90
-11.37%
IL:PPBT
Purple Biotech
1.00
-0.20
-16.67%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.